Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index

BACKGROUND: Immuno-oncology (IO) is rapidly evolving in early drug development. We aimed to develop and prospectively validate a prognostic index for patients treated in IO phase I trials to assist with patient selection. METHODS: The development cohort included 192 advanced solid tumor patients tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, Daphne, Guo, Christina, Kanjanapan, Yada, Tran, Ben, Spreafico, Anna, Joshua, Anthony M, Wang, Lisa, Abdul Razak, Albiruni R, Leighl, Natasha B, Hansen, Aaron R, Butler, Marcus O, Siu, Lillian L, Desai, Jayesh, Bedard, Philippe L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050022/
https://www.ncbi.nlm.nih.gov/pubmed/32337489
http://dx.doi.org/10.1093/jncics/pkz071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050022/
https://www.ncbi.nlm.nih.gov/pubmed/32337489
http://dx.doi.org/10.1093/jncics/pkz071

Ejemplares similares